Component pathogen inactivation: A critical review

Vox Sanguinis

Volumn 104, Issue 3, 2013, Pages 183-199

  Prowse, C V ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Clinical trial; Fresh frozen plasma; Pathogen inactivation; Platelet components; Red cell components; Review

Indexed keywords

AMOTOSALEN; AMUSTALINE; ANTIGEN; FRESH FROZEN PLASMA; METHYLENE BLUE; NEOANTIGEN; NONOXINOL 9; OCTAPLAS; RIBOFLAVIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM CONTAMINATION; BLOOD COMPONENT; BLOOD SAFETY; ERYTHROCYTE; GAMMA IRRADIATION; HUMAN; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOCYTE;

CLINICAL TRIAL; FRESH-FROZEN PLASMA; PATHOGEN INACTIVATION; PLATELET COMPONENTS; RED CELL COMPONENTS; REVIEW;

BLOOD PLATELETS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISINFECTION; ERYTHROCYTES; HUMANS; INFECTION CONTROL; PLASMA; ULTRAVIOLET RAYS;

EID: 84875585172     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01662.x     Document Type: Article

References (133)

1. Horowitz B, Bonomo R, Prince AM, et al. : Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79:826-831
2. Prowse CV: Pathogen inactivation of blood components. Transfus Alternat Transfus Med 2008; 10:139-146
3. Council of Europe, European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS), Symposium on Implementation of Pathogen Reduction Technologies for Blood Components September 2010 Executive Summary available at: http://www.edqm.eu/medias/fichiers/Executive_Summary_Pathogen_Reduction.pdf Accessed 5th November 2011
4. Corash L: Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep 2003; 2:495-502
5. Wollowitz S: Targeting DNA and RNA in pathogens: mode of action of amotosalen HCl. Transfus Med Hemother 2004; 31(Suppl 1):11-16
6. Kumar V, Lockerbie O, Keil SD, et al. : Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol, 2004; 80:15-21
7. Picker SM, Steisel A, Gathof BS: Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apheres Sci 2009; 40:79-85
8. Goodrich RP, Edrich RA, Li J, et al. : The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35:5-17
9. Marschner S, Fast LD, Baldwin WM III, et al. : White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50:2489-2498
10. Goodrich RP, Doane S, Reddy HL: Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38:20-30
11. Marschner M, Goodrich R: Pathogen reduction technology treatment of platelets, plasma and whole blood using Riboflavin and UV light. Transfus Med Hemother 2011; 38:8-18
12. Lambrecht B, Mohr H, Knüver-Hopf J, et al. : Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60:207-213
13. Williamson LM, Cardigan R, Prowse CV: Methylene Blue treated fresh frozen plasma: what is its contribution to blood safety?Transfusion 2003; 43:1322-1329
14. Prowse CV: Pathogen inactivation of blood components. Transfus Alternat Transfus Med 2008; 10:139-146
15. Seghatchian J, Struff WG, Reichenberg S: Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011; 38:55-64
16. Mohr H, Steil L, Gravemann U, et al. : A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49:2612-2624
17. Seltsam A, Müller TM: UVC Irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38:43-54
18. Irsch J, Lin L: Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system™. Transfus Med Hemother 2011; 38:19-31
19. Chavarin P, Cognasse F, Argaud C, et al. : In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™). Vox Sang 2011; 100:247-249
20. Moog R, Frohlich A, Mayaudon V, et al. : In vitro evaluation of single-donor platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apheresis 2004; 19:185-191
21. Isola H, Kientz D, Aleil B, et al. : In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006; 90:128-130
22. Singh Y, Sawyer LS, Pinkoski LS, et al. : Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46:1168-1177
23. Wagner SJ, Skripchenko A, Myrup A, et al. : Evaluation of in vitro storage properties of pre-storage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light. Transfusion 2009; 49:704-710
24. de Valensart N, Rapaille A, Goossenaerts E, et al. : Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA. Vox Sang 2009; 96:213-218
25. El-Ekiaby M, Sayed MA, Caron C, et al. : Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 2010; 20:48-61
26. Störmer M, Vollmer T, Kleesiek K, et al. : Spore-forming organisms in platelet concentrates: a challenge in transfusion bacterial safety. Transfus Med 2008; 18:371-376
27. Schmidt MS, Kapzrak B, Pfeiffer H-U, et al. : Efficiency of the pathogen inactivation System INTERCEPT under experimental conditions. Vox Sang 2011; 101 (Suppl 1): 226-227. P367
28. Störmer M, Arroyo A, Brachert J, et al. : Establishment of the first International Repository for Transfusion-Relevant Bacteria Reference Strains: ISBT Working Party Transfusion-Transmitted Infectious Diseases (WP-TTID), Subgroup on Bacteria. Vox Sang 2012; 102:22-31
29. Ciaravino V, McCullough T, Cimino G: The role of toxicology assessment in transfusion medicine. Transfusion 2003; 43:1481-1492
30. Ciaravino V, McCullough T, Cimino G, et al. : Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang 2003; 85:171-182
31. Ciaravino V, Hanover J, Lin L, et al. : Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion 2009; 49:985-994
32. North A, Ciaravino V, Mufti N, et al. : Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011; 51:2208-2218
33. Lin L, Conlan MG, Tessman J, et al. : Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005; 45:1610-1620
34. Reddy HL, Dayan AD, Cavagnaro J, et al. : Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22:133-153
35. Ambruso DR, Thurman G, Marschner S, et al. : Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion 2009; 49:2631-2636
36. Mohr H, Gravemann U, Bayer A, et al. : Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009; 49:1956-1963
37. Ruane PH, Edrich R, Gampp D, et al. : Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885
38. Stramer SL, Hollinger FB, Katz LM, et al. : Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49(Suppl 2):1S-29S
39. Goodrich RP, Custer B, Keil S, et al. : Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010; 50:1827-1837
40. Prowse CV, Murphy WG: Kills 99% of known germs. Transfusion 2010; 50:1636-1639, correction Transfusion 2011; 51: 447-448
41. Corash L, Lin L: Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004; 33:1-7
42. Marschner S, Fast LD, Baldwin WM, et al. : White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50:2489-2498
43. Roback JD, Conlan M, Drew WL, et al. : The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006; 20:45-56
44. Mintz PR: Cesium cessation? An advantage of pathogen reduction treatments. Transfusion 2011; 51:1369-1376
45. Prowse C: Pathogen inactivated plasma. Transfus Med Rev 2009; 23:124-133
46. AFSSAPS (Agence française de sécurité sanitaire des produits de santé). L'Afssaps recommande l'arrêt progressif de l'utilisation du plasma thérapeutique traité par le bleu de méthylène - Communiqué (12/10/2011). http://www.Afssaps.fr/Infos-de-securite/Communiques-Points-presse/L-Afssaps-recommande-l-arret-progressif-de-l-utilisation-du-plasma-therapeutique-traite-par-le-bleu-de-methylene-Communique/(language)/fre-FR (downloaded 6th November 2011).
47. AuBuchon JP, Herschel L, Roger J, et al. : Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45:1335-1341
48. Snyder E, Raife T, Lin L, et al. : Recovery and life span of 111-indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004; 44:1732-1740
49. Picker SM, Schneider V, Oustianskaia L, et al. : Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 49:2311-2318
50. Hambleton J, Wages D, Radu-Radulescu L, et al. : Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42:1302-1307
51. Hambleton J, Wages D, Radu-Radulescu L, et al. : The Kinetics of Proteins C & S Activity are Retained in INTERCEPT Plasma (IFFP) poster at Paris IST Congress July, 2001 (abstract)
52. de Alarcon P, Benjamin R, Dugdale M, et al. : Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45:1362-1372
53. Mintz PD, Bass NM, Petz LD, et al. : Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107:3753-3760
54. Mintz PD, Neff A, MacKenzie M, et al. : A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46:1693-1704
55. Horowitz MS, Pehta JC: SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74(Suppl 1):231-235
56. Pehta JC: Clinical studies with solvent detergent-treated products. Transfus Med Rev 1996; 10:303-311
57. Williamson LM, Llewelyn CA, Fisher NC, et al. : A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39:1227-1234
58. Wieding JU, Rathgeber J, Zenker D, et al. : Prospective randomized and controlled study on solvent/detergent versus methylene blue/light virus-inactivated plasma. Transfusion 1999; 39 (suppl):23s (abstract).
59. Beck KH, Mortelsmans Y, Kretschmer VV, et al. : Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed 2000; 27:144-148
60. Lerner RG, Nelson J, Sorcia E, et al. : Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000; 79:161-167
61. McCarthy LJ: The experience of treating patients with thrombotic thrombocytopenic purpura with solvent detergent plasma. Br J Haematol 2006;133:107 author reply 108 (letter)
62. de la Rubia J, Arriaga F, Linares D, et al. : Role of methylene blue-treated fresh frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001; 114:721-723
63. Alvarez-Larren A, Del Rio J, Ramirez C, et al. : Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004; 86:246-251
64. del Río-Garma J, Alvarez-Larrán A, Martínez C, et al. : Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143:39-45
65. Renaudier P, Schlanger S, Mai MPV, et al. : Epidemiology of transfusion related acute lung injury in France: preliminary results. Transfus Med Hemother. 2009; 35:89-91
66. del Río-Garma J, Pereira A, Arroyo JL, et al. : ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed by either the Springe method or an 'in house' system. Vox Sang 2008; 95:101-105
67. Ozier Y, Samain E, Gillon M-C, et al. : Plasma Transfusion in Liver Transplantation. http://www.ClinicalTrials.gov. ClinicalTrials.gov Identifier:NCT00235183. July 1, 2011. viewed 27th Dec 2011
68. Bartelmaos T: S14-3 - Comparaison de l'efficacité clinique de trois plasmas sécurisés sur le plan viral soit par traitement chimique soit par quarantaine dans le cadre des transplantations hépatiques oral presentation. Congres de la Société Française de Transfusion Sanguine, Lyon 4-6 Mai 2011 poster S14-3 http://www.sfts.asso.fr/index.php?option=com_content&view=article&id=92&Itemid=80
69. Dewachter P, Castro S, Nicaise-Roland P, et al. : Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 2011; 106:687-689
70. Nubret K, Delhoume M, Orsel I, et al. : Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 2011; 51:125-128
71. Cazenave JP, Waller C, Kientz D, et al. : An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50:1210-1219
72. van Rhenen D, Gulliksson H, Cazenave JP, et al. : Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426-2433
73. McCullough J, Vesole DH, Benjamin RJ, et al. : Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534-1541
74. Janetzko K, Cazenave JP, Klüter H, et al. : Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45:1443-1452
75. Slichter SJ, Raife TJ, Davis K, et al. : Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46:731-740
76. Simonsen AC, Johansson PI, Conlan MG, et al. : Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006; 46:424-433
77. Lozano M, Knutson F, Tardivel R, et al. : A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153:393-401
78. Kerkhoffs JL, van Putten WL, Novotny VM, et al. : Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209-217
79. The Mirasol Clinical Evaluation Study Group. (Cazenave J-P; Folléa G, Bardiaux L, et al.): A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-2375.
80. Goodrich R: Clarify the negatives of the MIRASOL non-inferiority trial. Transfusion 2011; 51:1362-1364
81. Davis KB, Slichter SJ, Corash L: Corrected count increment and percent platelet recovery as measures of post transfusion platelet response: problems and a solution. Transfusion 1999; 39:586-592
82. van Rhenen DJ, Gulliksson H, Cazenave JP, et al. : Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution. Transfus Med 2004; 14:289-295
83. Snyder E, McCullough J, Slichter SJ, et al. : Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45:1864-1875
84. Murphy S, Snyder E, Cable R, et al. : Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006; 46:24-33
85. Kerkhoffs J-LH: Evaluation of platelet transfusion clinical trials - response to Corash & Sherman. Br.J Haematol. 2011; 153:531-532
86. Corash L, Sherman CD: Evaluation of platelet transfusion clinical trials. Br J Haematol 2011; 153:529-531
87. Slichter SJ, Kaufman RM, Assmann SF, et al. : Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600-613
88. Osselaer JC, Messe N, Hervig T, et al. : A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061-1071
89. Cazenave JP, Waller C, Mendel I, et al. : Clinical experience with pathogen inactivation of platelet components for transfusion support; in Scharf RE (ed.): Progress and Challenges in Transfusion Medicine, Haemostasis and Hemotherapy. Basel, Karger, 2008: 248-263.
90. Cazenave JP, Waller C, Kientz D, et al. : An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50:1210-1219
91. Osselaer JC, Doyen C, Defoin L, et al. : Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:1412-1422
92. Cazenave JP, Isola H, Waller C, et al. : Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51:622-629
93. Schlenke P, Hagenah W, Irsch J, et al. : Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients. Ann Hematol 2011; 90:1457-1465
94. Infanti L, Stebler C, Job S, et al. : Pathogen-inactivation of platelet components with the INTERCEPT Blood System™: a cohort study. Transfus Apher Sci. 2011; 45:175-181
95. AFSSAPS annual haemovigilance reports for 2009-2011 available via http://www.afssaps.fr/Activites/Hemovigilance/Hemovigilance/(offset)/0 visited 18th May 2012.
96. Vamvakas EC: Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51:1058-1071
97. Corash L. The hemostatic efficacy of platelet components prepared with pathogen inactivation. Transfusion 2011; 51: 1355-1356. Vamvakas EC, reply Transfusion 2011; 51: 1356-1359
98. Cid J, Esolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012; 103:322-330
99. Vamvakas EC: Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102:302-316
100. Sherman C, Reed W, Corash L: Assessment of hemostasis in platelet transfusion clinical trials with differential follow-up, SP385. Transfusion 2011; 51(Suppl 3):188A
101. Klein HG, Anderson D, Bernardi MJ, et al. : Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47:2338-2347
102. Rasonglès P, Angelini-Tibert MF, Simon P, et al. : Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009; 49:1083-1091
103. Advisory Committee on the Safety of Blood Tissues & Organs (SABTO). Summary of the Ninth Meeting, 27 January 2010 available at http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_112479.pdf Accessed 5th November 2011.
104. AuBuchon JP, Prowse CV (eds). Pathogen Inactivation: The Penultimate Paradigm Shift. Bethesda, MD, AABB Press, 2010, 294, ISBN: 978-1-56395-309-5
105. Liu W, Cimino GD, Corash L, et al. : The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation. Transfusion 2011; 51:52-61
106. Isola H, Brandner D, Cazenave JP, et al. : Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label. Vox Sang 2010; 99:402
107. Allain JP, Hsu J, Pranmeth M, et al. : Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification. J Infect Dis 2006; 194:1737-1744
108. AuBuchon JP, Birkmeyer JD: Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994; 272:1210-1214
109. Jackson BR, AuBuchon JP, Birkmeyer JD: Update of cost-effectiveness analysis for solvent-detergent treated plasma. J Am Med Assoc 1999; 282:329-330
110. Pereira A: Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999; 39:479-487
111. Riedler GF, Haycox AR, Duggan AK, et al. : Cost effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003; 85:88-95
112. De Valensart N, Rapaille A, Meuter R, et al. : Plasma from whole blood treated with INTERCEPT Platelet processing set. Vos Sanguinis 2010; 99 (Suppl s1): 240. Poster P-0399
113. Sailliol A. Mise au point et perspectives sur le plasma lyophilisé. Congres de la Société Française de Transfusion Sanguine, Lyon 4-6 Mai 2011. oral presentation SOr3-1 http://www.sfts.asso.fr/index.php?option=com_content&view=article&id=92&Itemid=80.
114. Staginnus U, Corash L: The economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematology 2004; 80:317-324
115. Moeremans K, Warie H, Annemans L: Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006; 16:17-30
116. Postma MJ, van Hulst M, De Wolf JT, et al. : Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005; 15:379-387
117. Bell CE, Botteman MF, Gao X, et al. : Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003; 25:2464-2486
118. Custer B, Agapova M, Martinez RH: The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 50:2461-2473
119. Boyer J: Pathogen Reduction: Worth the Effort? A report from the AABB annual meeting 2011. downloaded 7th Nov 2011 http://www.aabb.org/events/annualmeeting/attendees/64amonline/Pages/tuesday_pathogen.aspx.
120. Henschler R, Seifried E, Mufti N: Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011; 38:33-42
121. Cook D, Merritt JE, Nerio A, et al. : Frangible compounds for pathogen inactivation. US Patent US 6, 514, 987 Bl. Feb.4th, 2003.
122. Mufti NA, Erickson AC, North AK, et al. : Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38:14-19
123. Pidcoke HF, Delgado KK, Mora AG, et al. : Pathogen reduction in whole blood with riboflavin and ultraviolet light does not affect platelet count or function. Transfusion 2011: 51 (Suppl. 3): 64A poster SP60.
124. Reddy H, Doane S, Marschner S, et al. : Riboflavin- and-UV-light-treated whole blood stored at room temperature for twenty-four hours compared to paired controls. Transfusion 2011; 51(Suppl 3):72A-73A.poster SP79
125. Tonnetti L, Thorp M, Reddy HL, et al. : Evaluation of Babesia microti Reduction with the Mirasol® System for Whole Blood. Transfusion 2011; 51(Suppl 3):27A.poster SP60-030F
126. Rios JA, Hambleton J, Viele M, et al. : Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006; 46:1778-1786
127. Cancelas JA, Dumont LJ, Rugg N, et al. : Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011; 51:2367-2376
128. Cancelas JC, Rugg N, Fletcher D, et al. : In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51:1460-1468
129. Benjamin RJ, McCullough J, Mintz PD, et al. : Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45:1739-1749
130. Conlan MG, Stassinopoulos A, Garratty G, et al. : Antibody formation to S-303-treated RBCs in the setting of chronic RBC transfusion [abstract]. Blood 2004;104:112-113(382).
131. Klein HG, Glynn SA, Ness PM, et al. : Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009; 49:1262-1268
132. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861-1869
133. Osselaer JC, Vandendaele M-C, Guldenpfennig M, et al. : Influence on HLA alloimmunisation frequency in hematology patients supported with INTERCEPT pathogen inactivated (PI) platelet components (PC). Transfusion 2011; 51(Suppl. 3):122A